Triumeq PD Generic: When Will It Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Triumeq PD Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? During 2028 Sometime that year Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? June 2030 2 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic abacavir sulfate, dolutegravir sodium, and lamivudine is expected to be available sometime in 2028. None is for sale yet.
Why 2028?
The patent fight is likely to end in an agreement that sets the launch. The terms are not public yet. We rate it probable: more likely than not, but it can still move.
If Triumeq PD’s last patent runs to June 2030, how can a generic come sooner?
The patent that runs to June 2030 (9,242,986) covers the active ingredient and the product’s formulation. A generic can still come sooner if a court rules a patent invalid or not infringed, or if the companies settle on an earlier date. Here, the companies are expected to settle on a date. Generic companies have been challenging Triumeq PD’s patents with the FDA since March 2023. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, and more so as more companies sell one. 4 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 73% less once four companies sold a generic. See the price pattern
What should I do now?
Keep taking Triumeq PD as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Triumeq PD by the Numbers
- Reason
- Settlement expectedThe patent fight is likely to end in an agreement that sets the launch. The terms are not public yet.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- Strong 4 companies have filed, 1 first in line
- Brand sales
- Sales not reported
- FDA approved 2022 March 2022 FDA Orange Book
- Patents listed 2 last runs to June 2030 A generic is expected sooner, sometime in 2028. See why FDA Orange Book
- Medicare Part D spent $19.9K in 2025 CMS Part D Spending by Drug
- Medicaid prescriptions 272 in the last four reported quarters, $518.1K CMS Medicaid drug utilization, to Q1 2026
Triumeq PD’s Road to a Generic
Triumeq PD has had the market to itself since the FDA approved it in March 2022 (Viiv Healthcare Co). Its FDA protection (pediatric) runs to December 2026. Its 2 listed patents run to June 2030. Generic companies have challenged its patents with the FDA since March 2023.
The first generic of Triumeq PD is expected sometime in 2028.
Why that month: the patent fight is likely to end in an agreement that sets the launch. The terms are not public yet.
Why a Generic Can Come Before June 2030
The last listed patent runs to June 2030; a court ruling or a settlement can bring a generic sooner. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Triumeq PD Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Triumeq PD’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,129,385 | The active ingredient; the product’s formulation | April 2028 with the pediatric extension | Active |
| 9,242,986 | The active ingredient; the product’s formulation | June 2030 with the pediatric extension | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New patient population NPP | Three years of protection for a newly approved group of patients. | June 2026 | Ended |
| Pediatric PED | Six more months, earned by studying the medicine in children. | December 2026 | Active |
Source: FDA Orange Book, application 215413. Patent numbers open the patent on Google Patents.
Patent Challenges to Triumeq PD
The first patent challenge to Triumeq PD reached the FDA in March 2023, from one company on that first day. The FDA has not approved a first challenger’s generic yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Triumeq PD’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Tablets for oral suspension, 60 mg/5 mg/30 mg | March 2023 | 1 company | No decision yet | Not yet | Not yet | December 2029 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Abacavir Sulfate, Dolutegravir Sodium, and Lamivudine
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
4 companies have applied to the FDA to make generic abacavir sulfate, dolutegravir sodium, and lamivudine.
The FDA names a company only once it approves its application, even tentatively, and it has not done that for these yet, so the companies are not named here. Names often come out in the brand company’s patent lawsuits or in the companies’ own announcements.
First in line. One of them was first in line: the first company to challenge the brand’s patents can earn 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Triumeq PD’s patents with the FDA since March 2023: see the patent challenges.
Approved by the FDA
Not yet. The FDA has not approved a generic abacavir sulfate, dolutegravir sodium, and lamivudine. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic abacavir sulfate, dolutegravir sodium, and lamivudine for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Triumeq PD Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Triumeq PD, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Triumeq PD
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Triumeq PD, before manufacturer rebates.
- $19.9K
- 2025, the whole year
About $1,244 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| 2025 | $19,907 | – | $1,244.21 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Triumeq PD only, so no generic is counted in it. What CMS says it is used for: This product contains 3 drugs: abacavir, dolutegravir, and lamivudine. It is used to help control HIV infection.
Medicaid Prescriptions by Quarter
272 prescriptions in the four quarters to Q1 2026, $518.1K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 51 | $103,324 |
| Q4 2025 | 90 | $168,931 |
| Q3 2025 | 91 | $178,113 |
| Q2 2025 | 40 | $67,746 |
| Q1 2025 | 60 | $113,161 |
Source: CMS Medicaid State Drug Utilization Data, over Triumeq PD’s own package codes.
Triumeq PD Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 60MG BASE;EQ 5MG BASE;30MG | Tablet, for suspension | Oral | March 2022 | Prescription reference product |
Source: FDA Orange Book, Viiv Healthcare Co. Listed for sale today by ViiV Healthcare Company (FDA NDC Directory).
Triumeq PD NDC Codes and Packages
Each Triumeq PD package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 49702-0258-37 | kit | 1 KIT in 1 CARTON * 90 TABLET, FILM COATED in 1 BOTTLE | ViiV Healthcare Company |
| 49702-0258-37 | kit | 1 KIT in 1 CARTON * 90 TABLET, FILM COATED in 1 BOTTLE | ViiV Healthcare Company |
Source: the FDA NDC Directory, current listings only. Only packages sold under Triumeq PD’s own FDA approval (NDA 215413) are listed, never a generic. Some codes belong to companies that repackage Triumeq PD: it is the same medicine in a different package.
What a Generic Triumeq PD Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Triumeq PD as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Triumeq PD”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Triumeq PD
Is there a generic for Triumeq PD right now?
No. As of October 9, 2026 no generic abacavir sulfate, dolutegravir sodium, and lamivudine is listed for sale in the FDA NDC Directory.
When will Triumeq PD go generic?
Sometime in 2028 is the expected window, and that is probable but not certain. The patent fight is likely to end in an agreement that sets the launch. The terms are not public yet. The last listed patent runs to June 2030; a court ruling or a settlement can bring a generic sooner.
Will generic abacavir sulfate, dolutegravir sodium, and lamivudine be the same as Triumeq PD?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. 4 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid about 73% less once four companies sold a generic. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Triumeq PD?
Not yet. The FDA Orange Book lists no approved generic version of Triumeq PD.
When does the Triumeq PD patent expire?
The FDA Orange Book lists 2 patents for Triumeq PD; the last runs to June 2030, counting a six-month pediatric extension. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (Sometime in 2028) weighs all of that.
Has anyone challenged the Triumeq PD patents?
Yes. The first patent challenge to Triumeq PD reached the FDA in March 2023, from one company on that first day. The FDA has not approved a first challenger’s generic yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
Changes to This Projection
- First generic expected Sometime in 2028 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- Arymo ERMorphine Sulfate2026 to 2027
- Jentadueto XRLinagliptin and Metformin HydrochlorideJuly to December 2026
- VumerityDiroximel FumarateDuring 2033
- OnivydeIrinotecanOctober 2036
- EmbedaMorphine Sulfate and Naltrexone HydrochlorideTBD no date yet
- Sotalol Hydrochloride IVSotalol HydrochlorideTBD no date yet
About Triumeq PD
- Generic name abacavir sulfate, dolutegravir sodium, and lamivudine
- How it is taken By mouth
- Company Viiv Healthcare Co
- Patent challenges Since March 2023 (FDA)
- More drugs Brand-name drugs starting with T
- Have a question? A pharmacist answers, free. Ask about Triumeq PD
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.